PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: Placebo ointment (vehicle)
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT03233529
- Locations
- ๐จ๐ฆ
Innovaderm Research Incorporated, Montreal, Quebec, Canada
Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03232905
- Locations
- ๐ง๐ช
Pfizer Clinical Research Unit, Brussels, Belgium
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT03230383
- Locations
- ๐ง๐ช
Pfizer Clinical Research Unit, Brussels, Belgium
๐บ๐ธPfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
- Conditions
- Lung Neoplasms
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4240
- Registration Number
- NCT03220230
- Locations
- ๐ง๐ท
Hospital Santa Izabel, Salvador, Brazil
๐ง๐ทCentro Regional Integrado de Oncologia, Fortaleza, Caera, Brazil
๐ง๐ทInstituto Goiano de Oncologรญa e Hematologia, Aparecida De Goiana, Goias, Brazil
Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03220191
- Locations
- ๐บ๐ธ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT03217604
- Locations
- ๐ง๐ช
Pfizer Clinical Research Unit, Brussels, Belgium
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Other: Placebo oral solution/suspensionDrug: PF-06826647 tabletOther: Placebo tabletDrug: PF-06826647 oral suspension
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 109
- Registration Number
- NCT03210961
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).
- Conditions
- Meningococcal ACWY Disease
- Interventions
- Biological: MenACWY-TT
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 229
- Registration Number
- NCT03189745
- Locations
- ๐ต๐ญ
Research Institute for Tropical Medicine, Muntinlupa City, Metro Manila, Philippines
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
- Conditions
- Parkinson's Disease With Motor Fluctuations
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT03185481
- Locations
- ๐บ๐ธ
Associated Neurologists of Southern CT, PC, Fairfield, Connecticut, United States
๐บ๐ธHoag Memorial Hospital Presbyterian, Newport Beach, California, United States
๐บ๐ธPharmaceutical Research Associates, Inc., Marlton, New Jersey, United States
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]lorlatinib
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03184168
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States